GT Biopharma, Inc. (GTBP)

Nasdaq: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

March 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

January 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

December 2025 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

About

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE^®) technology. TriKE^® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.

Latest News

GT Biopharma Reports First Quarter 2026 Financial Results
May 15, 2026 • 8:00 EDT | Read More

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
May 14, 2026 • 8:30 EDT | Read More

Investors

GT Biopharma, Inc. Nasdaq: GTBP

Change

Volume

52 Week Range

View Our Investor Relations